EXTON, PA — West Pharmaceutical Services Inc. (NYSE: WST) completed the sale and transfer of manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System on July 1, narrowing its device portfolio while retaining other SmartDose platforms.
The transaction included associated facilities tied to the 3.5mL system, the company reported. Financial terms were not disclosed.
West will continue to develop and manufacture other SmartDose versions, including its 10mL On-Body Delivery System, which is designed for larger-volume injectable drug delivery.
The sale marks a portfolio adjustment for the Exton-based company, which supplies injectable drug containment and delivery products to pharmaceutical and biotechnology customers.
West reported $3.07 billion in net sales for fiscal 2025. The company has more than 10,000 employees across 50 sites, including 26 manufacturing facilities, and delivers more than 41 billion components and devices annually.
West is listed on the New York Stock Exchange and is included in the S&P 500 index.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.